Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio PartnersCompany’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) moleculesFounding team comprised of world-class scientific leadersWATERTOWN, Mass. (BUSINESS WIRE) Entact B.
4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AACR and MPM award three grants to support groundbreaking cancer research projects
Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital.
The Transformative Cancer Research Grants Program provides generous funds to investigators so they can pursue innovative research which has the potential to help guide and advance cancer treatment and make a significant impact for cancer patients. These grants are part of OIF s impact program, which provides support for next-generation basic science research as well as patient access to oncology drugs through the UBS Optimus Foundation. OIF donates a percentage of the fund manager s profits to the impact program, as well as royalties on approved drugs from OIF startup portfolio com
E-Mail
PHILADELPHIA, PA and CAMBRIDGE, MA - January 19, 2021 Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital.
The Transformative Cancer Research Grants Program provides generous funds to investigators so they can pursue innovative research which has the potential to help guide and advance cancer treatment and make a significant impact for cancer patients. These grants are part of OIF s impact program, which provides support for next-generation basic science research as well as patient access to oncology drugs through the UBS Optimus Foundation. OIF donates a percentage of the fund manager s profits to the impact program, as well as royalties on approved drugs from OIF startup portfolio companies. To dat